Inhibition of Labile Aggregation-stimulating Substance (LASS) and Platelet Aggregation in Diabetes Mellitus

Publisher Website
Google Scholar
Abstract
Irreversible second-phase aggregation of platelets in diabetic patients is prevented in vitro by 5, 8, 11, 14-eicosatetraynoic acid (TYA), a competitive inhibitor of the labile aggregationstimulating substance (LASS) which is formed from arachidonic acid. Thus, inhibition of prostaglandin synthesis inhibits platelet aggregation in diabetic subjects. These findings indicate that platelets from diabetics are subject to control by intracellular mechanisms operative in the regulation of platelet function in normal individuals.

This publication has 0 references indexed in Scilit: